

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G

LYNX THERAPEUTICS INC  
Form SC 13G  
May 20, 2002

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No.            ) \*

LYNX THERAPEUTICS

-----  
(Name of Issuer)

Common

-----  
(Title of Class of Securities)

000551812308

-----  
(CUSIP Number)

5/17/02

-----  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

/x/ Rule 13d-1(b)

/ / Rule 13d-1(c)

/ / Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 000551812308  
-----

-----  
(1) Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

Hambrecht & Quist Capital Management 943021090  
-----

(2) Check the Appropriate Box if a Member   (a)   / /

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G

of a Group (See Instructions)

(b) /x/

(3) SEC Use Only

(4) Citizenship or Place of Organization  
California Corp.

Number of Shares Beneficially Owned by Each Reporting Person With: (5) Sole Voting Power  
1,985,000

(6) Shared Voting Power

(7) Sole Dispositive Power

(8) Shared Dispositive Power

(9) Aggregate Amount Beneficially Owned by Each Reporting Person  
1,985,000

(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) / /

(11) Percent of Class Represented by Amount in Row (9)  
7.0%

(12) Type of Reporting Person (See Instructions)  
IA

SCHEDULE 13G EXHIBIT

ITEM 1.

Lynx Therapeutics  
25861 Industrial Blvd.  
Hayward, CA 94545

ITEM 2.

Hambrecht & Quist Capital Management Incorporated  
30 Rowes Wharf - 4th Floor  
Boston, MA 02110-3328  
(California corporation)

Common stock  
CUSIP: 000551812308

ITEM 3.

(e) Investment Adviser

ITEM 4.

Hambrecht & Quist Capital Management Incorporated ("HQCM") disclaims any beneficial interest in the shares reported in this Schedule 13G. Moreover, HQCM is of the view that the client accounts that it manages are not acting as a "group" for purposes of Section 13(d) under the Securities and Exchange Act of 1934 (the "1934 Act") and that it and such clients are not otherwise required to attribute to each other the "beneficial ownership" of securities "beneficially owned" under Rule 13d-3 promulgated under the 1934 Act. Therefore, HQCM is of the view that the shares held in such accounts should

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G

not be aggregated for purposes of Section 13(d). However, HQCM is making this filing on a voluntary basis as if all the shares are beneficially owned by HQCM on a joint basis.

1,985,000 shares of Common stock beneficially owned 7.0% of Common 1,985,000 sole voting power (i) and sole dispositive power (iii)

ITEM 5.

N/A

ITEM 6.

N/A

ITEM 7.

N/A

ITEM 8.

N/A

ITEM 9.

N/A

ITEM 10.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.

E-1

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: 5/17/02

Signature: /s/ KIM CARROLL

Name/Title: Kim Carroll, Vice President  
Hambrecht & Quist Capital Management Incorporated

E-2